Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008

NCT01903733 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01903733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
Lead sponsor
Pfizer
Phase
Not applicable
Overall status
Completed
Start date
August 28, 2013
Completion date
June 5, 2020
Enrollment
281 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia